PDT Partners LLC Purchases New Shares in REGENXBIO Inc. (NASDAQ:RGNX)

PDT Partners LLC purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 63,015 shares of the biotechnology company's stock, valued at approximately $487,000. PDT Partners LLC owned about 0.13% of REGENXBIO as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in RGNX. JPMorgan Chase & Co. grew its holdings in REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after buying an additional 1,659,206 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of REGENXBIO in the fourth quarter valued at approximately $3,865,000. Norges Bank bought a new position in REGENXBIO during the fourth quarter worth $3,474,000. Voss Capital LP acquired a new position in REGENXBIO during the 4th quarter valued at $2,573,000. Finally, Assenagon Asset Management S.A. raised its stake in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Stock Up 5.8 %

NASDAQ:RGNX traded up $0.57 during trading hours on Friday, reaching $10.40. The company had a trading volume of 1,015,830 shares, compared to its average volume of 824,606. The stock has a 50-day moving average of $7.16 and a two-hundred day moving average of $8.07. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $17.35. The firm has a market capitalization of $521.22 million, a PE ratio of -2.07 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, sell-side analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RGNX has been the topic of several research reports. HC Wainwright dropped their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Morgan Stanley lifted their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. The Goldman Sachs Group lowered their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, Raymond James began coverage on REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.